<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019080</url>
  </required_header>
  <id_info>
    <org_study_id>180293</org_study_id>
    <nct_id>NCT04019080</nct_id>
  </id_info>
  <brief_title>Real-Life Use of Anti-fibrotic Drugs in Patients With Idiopathic Pulmonary Fibrosis in Sweden</brief_title>
  <official_title>Real-Life Use of Anti-fibrotic Drugs in Patients With Idiopathic Pulmonary Fibrosis in Sweden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the current research project is, by using high quality Swedish registry
      data, to evaluate use, tolerance and effect of anti-fibrotic drugs in IPF-patients. Secondary
      study objectives are to determine the clinical profile, determinants of treatment adherence,
      long-term safety and to describe the patient journey from the first sign of disease to end of
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-fibrotic drugs among the patients recorded in the Swedish IPF-registry</measure>
    <time_frame>2014-2020</time_frame>
    <description>The use of anti-fibrostic drugs</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anti-fibrostic drugs</intervention_name>
    <description>The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with idiopathic pulmonary fibrosis included in the Swedish IPF-registry
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects included in the Swedish IPF-registry

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlson, RN</last_name>
    <phone>+46737121597</phone>
    <email>lisa.carlson@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sköld, Prof</last_name>
    <email>magnus.skold@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlson, RN</last_name>
      <phone>+46737121597</phone>
      <email>lisa.carlson@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Sköld, Prof</last_name>
      <email>magnus.skold@ki.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Magnus Skold</investigator_full_name>
    <investigator_title>Professor, Senior consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

